Efaproxiral (Standard)
Efaproxiral (Standard) is the analytical standard of Efaproxiral. This product is intended for research and analytical applications. Efaproxiral is a haemoglobin (Hb) synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy [1].
Product Specifications
CAS Number
131179-95-8
UNSPSC
12352100
Target
Reactive Oxygen Species (ROS) ; Reference Standards
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Others
Field of Research
Cancer
Smiles
CC(C)(OC1=CC=C(CC(NC2=CC(C)=CC(C)=C2)=O)C=C1)C(O)=O
Molecular Formula
C20H23NO4
Molecular Weight
341.40
References & Citations
[1]Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94 (12) :1777-1784.|[2]Abraham DJ, et al. Allosteric modifiers of hemoglobin: 2-[4-[[ (3,5-disubstituted anilino) carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry. 1992 Sep 29;31 (38) :9141-9.|[3]Hou H, et al. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice. Radiat Res. 2007 Aug;168 (2) :218-25.|[4]Hou H, et al. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61 (5) :1503-9.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNCB2697-100 1x 100 µL
PMEPA1 / TMEPAI (Tumor Suppressor Oncoprotein) (PMEPA1/2697), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040142-100 1x 100 µL
Beta-2 Microglobulin (B2M) (BBM.1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 